C-FLOX 250 TABLETS 250 mg

Kraj: Singapur

Język: angielski

Źródło: HSA (Health Sciences Authority)

Składnik aktywny:

CIPROFLOXACIN HCl EQV CIPROFLOXACIN

Dostępny od:

APOTHECA MARKETING PTE LTD

Kod ATC:

J01MA02

Dawkowanie:

250 mg

Forma farmaceutyczna:

TABLET, FILM COATED

Skład:

CIPROFLOXACIN HCl EQV CIPROFLOXACIN 250 mg

Droga podania:

ORAL

Typ recepty:

Prescription Only

Wyprodukowano przez:

INTAS PHARMACEUTICALS LTD

Status autoryzacji:

ACTIVE

Data autoryzacji:

2000-04-07

Charakterystyka produktu

For the use of a Registered Medical Practitioner or a Hospital or a
Laboratory.
C-FLOX 250 & 500
(Ciprofloxacin Tablets USP 250 mg & 500 mg)
COMPOSITION:
Each tablet contains:
Ciprofloxacin Hydrochloride USP
Equivalent to Ciprofloxacin 250 mg & 500 mg
C-Flox is a broad spectrum and potent synthetic fluoroquinolone
antibacterial agent. It is indicated in various respiratory, urinary
and
other infections caused by susceptible microorganisms.
CLINICAL PHARMACOLOGY:
Ciprofloxacin exhibits potent bactericidal action by interfering with
enzyme DNA gyrase which is needed for the synthesis of bacterial
DNA. The in vitro antimicrobial spectrum of Ciprofloxacin includes
wide range of microorganisms including Gram-negative bacteria
like campylobacter jejuni, E. coli, Citrobacters, H. influenzae, H.
parainfluenzae,
Shigella,
Salmonella
typhi,
Vibrio
cholerae,
Neisseria gonorrhoea, N. meningitidis, Branhaemella catarrhalis,
Kleb.
pneumoniae,
Brucella
melitensis,
H.ducrayi,
Proteus
mirabilis,
P.vulgaris,
Pseudomonas
aeruginosa,
Providancia
rettgeri, P. startii, Serratia marcescens, Enterobacter cloacae, and
Gram-positive
bacteria
like
Staphylococcus
aureus,
Staph.
epidermidis,
Staph.
haemolyticus,
Streptococcus
pneumoniae,
Streptococcus
pyogenes.
Most
strains
of
Ps.
cepacia,
Ps.
multophilia
and
most
anaerobic
bacteria
are
resistant
to
Ciprofloxacin. Ciprofloxacin is slightly less active at acidic pH.
Ciprofloxacin does not cross-react with other antimicrobial agents.
Synergism
is
reported
with
aminoglycosides,
clindamycin,
metronidazole and particularly beta-lactams. Ciprofloxacin is also
shown
to
have
post
antibiotic
effect
(PAE)
i.e.
continued
antibacterial effect after cessation of drug administration.
Ciprofloxacin is rapidly and well absorbed from the gastrointestinal
tract.
Oral
bioavailability
is
about
70%
and
a
peak
plasma
concentration of about 2.5 mcg per ml is achieved 1 to 2 hours after
a dose of 500 mg by mouth. Absorption is delayed in presence of
food. Plasma protein binding ranges from 20 to 40%. Ciprofloxacin